Prognostic factors for the response to tocilizumab therapy in patients with juvenile idiopathic arthritis without systemic manifestations: A cohort...
Алексеева Е. И., Дворяковская Т. М., Исаева К. Б., Слепцова Т. В., Денисова Р. В., Солошенко М. А., Ломакина О. Л., Фетисова А. Н., Рудниcкайа М. Г., Ванкова Д. Д., Алшевскайа А. А., Москалев А. В., Мамутова А. В.
Вопросы современной педиатрии
Т. 17, Вып. 3, С. 207-215
Опубликовано: 2018
Тип ресурса: Статья
DOI:10.15690/vsp.v17i3.1889
Аннотация:
Background. To assign genetically engineered biologic drugs, we need data on the predictors for response to therapy. Prognostic factors for the response to tocilizumab in patients with juvenile idiopathic arthritis (JIA) without systemic symptoms are poorly studied. Objective. Our aim was to reveal early predictors for the response to tocilizumab therapy in patients with JIA without systemic symptoms. Methods. A retrospective cohort study enrolled patients with JIA without systemic symptoms who received tocilizumab therapy between July 2009 and August 2017. We assessed the association between the initial demographic, clinical, and laboratory parameters in patients and the best response (according to the ACR90 criteria) to treatment after a year. Results. The study included 95 (girls 85[%]) patients; the mean age was 10.3 (6.0; 13.6). During the first year of therapy, 71 (75[%]), 55 (58[%]), 38 (40[%]), and 22 (23[%]) patients achieved the improvement according to ACR30/50/70/90 criteria, respect
Ключевые слова:
Children; Genetically engineered biologic drug; Juvenile idiopathic arthritis; Response predictors; Therapy; Tocilizumab
C reactive protein; tocilizumab; adolescent; arthritis; Article; child; cohort analysis; disease activity score; disease course; dose response; drug efficacy; female; human; juvenile rheumatoid arthritis; leukopenia; major clinical study; male; multivariate analysis; neutropenia; onset age; outcome assessment; parent; patient assessment; predictor variable; preschool child; prognostic assessment; protein blood level; retrospective study; school child; treatment duration; treatment outcome; urticaria; visual analog scale
Язык текста: Русский
ISSN: 1682-5535
Алексеева Е. И. Екатерина Иосифовна 1962-
Дворяковская Т. М. Татьяна Маратовна 1975-
Исаева К. Б.
Слепцова Т. В.
Денисова Р. В.
Солошенко М. А.
Ломакина О. Л.
Фетисова А. Н.
Рудниcкайа М. Г.
Ванкова Д. Д.
Алшевскайа А. А.
Москалев А. В.
Мамутова А. В.
Alekseeva E. I. Ekaterina Iosifovna 1962-
Dvoryakovskaya T. M. Tat`yana Maratovna 1975-
Isaeva K. B.
Sleptsova T. V.
Denisova R. V.
Soloshenko M. A.
Lomakina O. L.
Fetisova A. N.
Rudnickaya M. G.
Vankova D. D.
Alshevskaya A. A.
Moskalev A. V.
Mamutova A. V.
Prognostic factors for the response to tocilizumab therapy in patients with juvenile idiopathic arthritis without systemic manifestations: A cohort study
Prognostic factors for the response to tocilizumab therapy in patients with juvenile idiopathic arthritis without systemic manifestations: A cohort...
Текст визуальный непосредственный
Вопросы современной педиатрии
Издательство "Педиатръ"
Т. 17, Вып. 3 С. 207-215
2018
Статья
Children Genetically engineered biologic drug Juvenile idiopathic arthritis Response predictors Therapy Tocilizumab
C reactive protein tocilizumab adolescent arthritis Article child cohort analysis disease activity score disease course dose response drug efficacy female human juvenile rheumatoid arthritis leukopenia major clinical study male multivariate analysis neutropenia onset age outcome assessment parent patient assessment predictor variable preschool child prognostic assessment protein blood level retrospective study school child treatment duration treatment outcome urticaria visual analog scale
Background. To assign genetically engineered biologic drugs, we need data on the predictors for response to therapy. Prognostic factors for the response to tocilizumab in patients with juvenile idiopathic arthritis (JIA) without systemic symptoms are poorly studied. Objective. Our aim was to reveal early predictors for the response to tocilizumab therapy in patients with JIA without systemic symptoms. Methods. A retrospective cohort study enrolled patients with JIA without systemic symptoms who received tocilizumab therapy between July 2009 and August 2017. We assessed the association between the initial demographic, clinical, and laboratory parameters in patients and the best response (according to the ACR90 criteria) to treatment after a year. Results. The study included 95 (girls 85[%]) patients; the mean age was 10.3 (6.0; 13.6). During the first year of therapy, 71 (75[%]), 55 (58[%]), 38 (40[%]), and 22 (23[%]) patients achieved the improvement according to ACR30/50/70/90 criteria, respect